Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

J&J, Pfizer Alzheimer’s Study Will Be Presented in Early October

June 20 (Bloomberg) -- Researchers will present the results of two late-stage studies on Johnson & Johnson and Pfizer Inc.’s experimental drug for Alzheimer’s disease, bapineuzumab, at the American Neurological Association meeting in early October.

The findings of the two studies will be presented in Boston on Oct. 8 in a session dedicated to immune-based treatments for neurological disorders, according to the meeting program posted on the neurological association’s website. The results, if positive, could lead the companies to file for U.S. Food and Drug Administration approval of the medicine.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at

To contact the editor responsible for this story: Reg Gale at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.